Matthew Kulke, MD

Matthew Kulke, MD, director, Neuroendocrine and Carcinoid Tumors Program, Dana-Farber Cancer Institute, discusses treatment options on the horizon in the treatment of neuroendocrine tumors (NETs) during the 2017 NANETS Symposium.